Neutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

Perez Fidalgo, J. A.Cortes, A.Garcia, Y.Iglesias, M.Bohn Sarmiento, U.Calvo Garcia, E.Manso, L.Santaballa, A.Oaknin, A.Redondo, A.Rubio, M. J.Gonzalez-Martin, A.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/25899enNeutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601conference outputopen access10.1016/j.annonc.2021.08.11771569-8041https://doi.org/10.1016/j.annonc.2021.08.1177700527701201